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PaediatricSickle cell disease (SCD) is a genetic disorder characterised by anaemia and “sickling” of red blood cells, leading to
chronic haemolytic anaemia, vascular injury, and organ dysfunction. Although children and adults experience
many similar symptoms and problems, complications increase with age, leading to early mortality. Hydroxyurea
(hydroxycarbamide), the only US Food and Drug Administration-approved treatment, continues to be under-
utilised and other treatments available to children are often inaccessible for adults. Haematopoietic stem-cell
transplantation is a curative option, but is limited by a lack of donors and concerns for transplant-related toxic-
ities. Although comprehensive programs exist in paediatrics, affected adults may not have access to preventative
and comprehensive healthcare because of a lack of providers or care coordination. They are often forced to rely on
urgent care, leading to increased healthcare utilisation costs and inappropriate treatment. This problem high-
lights the importance of primary care during the transition from paediatrics to adulthood.
© 2013 Elsevier Ltd. All rights reserved.1. Introduction
Sickle cell disease (SCD), the most common inherited red blood cell
(RBC) disorder, affects individuals of African, Mediterranean, and Asian
descent and manifests as haemolysis and vaso-occlusion [1]. Patients
experience a spectrum of disease symptoms and complications, includ-
ing periods of acute pain (vaso-occlusive episodes [VOE]), chronic pain,
multi-organ injury, reduced quality of life, and a shortened lifespan [1,2].
Worldwide it is estimated that over 200,000 children affected with SCD
are born every year, primarily in sub-Saharan Africa (180,000 births
per year) [3,4]. Approximately 2000 children in the US [5] are born
with SCD each year, with a disease incidence of 1 in 2474 live births
(newborn screening data 1990–1999) [6]; the estimated US prevalence
ranges from 70,000–140,000 [7,8].
Among individuals with the homozygous sickle haemoglobin muta-
tion (HbSS) living in ﬁrst-world countries, the estimated mean life
expectancy is 39 years [8], which has improved signiﬁcantly over the
last few decades. Increased overall survival of paediatric patients with
SCD [9] (Fig. 1) can be attributed to the landmark Prophylactic Penicillin
Study (PROPS; 1986), [10] which demonstrated that the use of prophy-
lactic penicillin could prevent life-threatening infections in affected
children. Thus, universal newborn screening became standard practice
in the US in the late 1990s and in the United Kingdom in the early
2000's [10–12], enabling early diagnosis and patient management. The
introduction of a pneumococcal conjugate vaccine also signiﬁcantly
contributes to decreased SCD mortality in children younger thanth Carolina, 135 Rutledge Ave,
: +1 843 792 8912.
ghts reserved.10 years of age [12,13]. However, in low-resource countries, more
than 50% of children younger than 5 years of age die due to complica-
tions of SCD [14].
Becausemore than 98%of childrenwithmilder forms of SCD in high-
resource countries are living into adulthood, SCD is now a chronic
condition requiring comprehensive, life-long management [9]. Speciﬁc
challenges for this emerging adult population include difﬁculty in man-
aging the transition from paediatric to adult care because of a lack of
available healthcare providers for adults with SCD. Thus, adults with
SCD often rely on emergency department (ED) physicians and inpatient
treatment for their care. The aim of this review is to familiarize primary
care physicians, inpatient hospitalists, and ED physicians with the cur-
rent understanding and management of SCD.
2. Pathophysiology of SCD
SCD is the result of a single-pointmutation (replacement of glutamic
acid with valine in position 6) on the β-globin subunit of haemoglobin
[1], resulting in a mutant form of haemoglobin known as sickle
haemoglobin (HbS). Peoplewho inherit two copies of the HbSmutation
are homozygous (HbSS) and have the disease phenotype, whereas het-
erozygous carriers (HbAS) do not exhibit clinical disease (known as
sickle cell trait). Other forms of SCD occur when mutations responsible
for other aberrant types of haemoglobin (C or E) or for β-thalassemia
combinewithHbS as a compoundheterozygousmutation (haemoglobin
genotypes SC, SE, Sβ+, or Sβ0). Persons with HbSS and HbSβ0 have the
most severe forms of SCD.
HbS polymerizes under low oxygen conditions (e.g. stress, hypoxia,
or acidosis), resulting in deformed and fragile RBCs that have a charac-
teristic sickle (half-moon) shape and a reduced lifespan (from 120 days
Fig. 1. Improvements in survival of childrenwith sickle cell disease (SCD). Trends in over-
all survival for children with sickle cell anaemia and sickle β0-thalassemia by cohort era.
Note: Cohort eras are deﬁned by year of birth (1983–1990, 1991–1999, and 2000–2007).
Republishedwith permission of American Society of Hematology, from Improved survival
of children and adolescents with sickle cell disease. Quinn CT, Rogers ZR, McCavit TL,
BuchananGR. [Blood 2010;115:3447-52]; permission conveyed throughCopyright Clearance
Center, Inc.
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lation, leading to tissue ischaemia, infarction, and chronic haemolytic
anaemia (Fig. 2) [15]. In addition to vaso-occlusion, breakdown of
the sickle RBC results in chronic haemolytic anaemia, which increases
free haemoglobin production. This pathophysiologic process results in
inﬂammation, platelet activation, increased adhesion of RBCs to theFig. 2. Pathophysiology of vaso-occlusion in SCD. Arg, arginine; ESL-1, E-selectin ligand-1; ET-1, e
RBC, red blood cell; SCD, sickle cell disease; XO, xanthine oxidase.
Adapted from Brown [15], Hebbel et al. [75], Tailor et al. [76], Looney et al. [17], and Gladwin etvascular endothelium, and abnormal nitric oxide metabolism [16].
Platelet activation yields alpha granule excretion of inﬂammatory
markers, such as P-selectin, that further increases adhesion of RBCs
and platelets to the vascular endothelium. Sequestered neutrophils
also interact with the endothelium mediated by E-selectin ligand-1
[17], which exacerbates tissue damage (Fig. 3). These abnormalities
combine to produce a multi-system disorder of chronic inﬂammation,
blood vessel damage, and anaemia. As the pathophysiologic abnormal-
ities in SCD are better understood, newer targets for treatment have
been identiﬁed.
3. Clinical manifestations of SCD
SCD shows considerable phenotypic heterogeneity resulting from
both genetic and environmental factors. It is a multi-organ disease in
which patients experience a range of symptoms and complications that
worsens with age (Table 1) [1,2,18–20].
Pain (acute or chronic) is the hallmark feature of SCD [15]. It can
result from small vessel blockage/constriction and subsequent tissue
infarction, organ impairment, or be idiopathic. VOEs are severe, acute
painful episodes that result from vaso-occlusion with inﬂammatory and
ischaemic consequences [21]. VOEs can occur throughout the body, in-
cluding bones,muscles,mesentery, andother organs [1,2,18–20]. Chronic
pain, which is poorly understood, can be debilitating andmay result from
leg ulcers, avascular necrosis, and/or neuropathic complications.
Other deﬁned sickle cell crises include sequestration crisis (pooling
of blood in an organ), aplastic crisis (reduced function of bonemarrow),
haemolytic crisis (a rapid breakdown of blood cells causing a drop
in haemoglobin levels), acute chest syndrome (ACS), or other acute
organ damage (including myocardial infarction), and stroke [1,15]. Inndothelin-1; Hb, haemoglobin; NO, nitric oxide; NOS, nitric oxide synthase; O2−, superoxide;
al. [77].
Fig. 3. Complications of SCD: childhood and adulthood [18]. CAD, coronary artery disease; SCD, sickle cell disease.
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and are at risk for numerous life-threatening complications, such as sep-
sis, stroke, ACS, multi-organ injury progressing to end-organ damage,
pulmonary embolism, pulmonary hypertension, cardiomyopathy, and
hepatic disease [1]. In addition to the above complications, patients
often have a shortened lifespan, a reduced quality of life, and signiﬁcant
anxiety and depression as well [22].Table 1
Clinical manifestations of paediatric and adult SCD [1,2,18–20].
Paediatric SCD
Symptoms
Infants
Pain in chest, abdomen, and limbs/joints
Dactylitis
Anaemia
Mild jaundice
Enlarged spleen
Fever
Frequent upper respiratory infections
Children
Pain (acute o
Acute anaem
Infections
Jaundice
Poor nutrition
Academic fail
Delayed pube
Complications
CNS Stroke
Eye Retinal artery occlusion/retinopathy
Lung ACS
Asthma
Heart Left ventricular hypertrophy
Cardiomyopathy
Spleen Acute splenic sequestration
Auto-infarction
Impaired immunity (e.g. bacterial infection, sepsis)
Liver
Kidney Hyposthenuria
Proteinuria
Renal impairment/failure
Gall bladder Cholelithiasis
Genitals Priapism
Bones/joints Avascular necrosis
Aplastic crisis
Skin Chronic ulcers, typically on the ankles
SCD, sickle cell disease; CNS, central nervous system; ACS, acute chest syndrome.4. Symptoms and complications
4.1. Infants/children
Infants with SCD can presentwith symptoms beginning at 6 months
of age (as foetal haemoglobin dissipates) with dactylitis (painful swell-
ing of the hands or feet), anaemia, mild jaundice, or an enlarged spleenAdult SCD (additional symptoms and complications)
r chronic)
ia
al status and growth
ure
rty
Severe joint pain
Chronic leg ulcers
Retinopathy
Thromboembolic complications
Neurocognitive impairments
Narcotic dependence/tolerance
Recurrent ischemic stroke, haemorrhagic stroke
Progressive retinopathy
Recurrent ACS
Pulmonary hypertension
Chronic lung disease
Premature coronary artery disease
Heart failure
Functional asplaenia
Hepatic sequestration
Liver failure secondary to transfusional iron overload
Nephropathy
Frequent urinary tract infections
Cholelithiasis
Priapism
Avascular necrosis
Early loss of bone density
Chronic leg ulcers
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atric SCD are pain, infection, acute splenic sequestration, ACS, and
stroke. Poor splenic function results in a compromised immune system
and increased susceptibility to infection (including sepsis), which is the
primary cause of mortality in paediatric patients [1]. Penicillin prophy-
laxis and anti-pneumococcal vaccination have signiﬁcantly decreased
the incidence of life-threatening infections in children with SCD in re-
gions inwhich these treatments are utilised [23,24]. Newborn screening
programs are slowly being initiated in parts of Africa, including Ghana,
but many affected individuals are still without access to these necessary
prevention measures [14].
4.2. Acute chest syndrome
ACS often presents with clinical symptoms similar to pneumonia. In
high-resource countries, ACS is the greatest cause of mortality after
2 years of age in patients with SCD, the leading cause of admissions to
the paediatric intensive care unit, and the second-most common cause
of hospital admission after VOE [9,17]. ACS is caused by vaso-occlusion
in the pulmonary vasculature and is clinically described as the combina-
tion of hypoxia, fever, and a new inﬁltrate identiﬁed on chest X-ray.
However, the clinical symptoms of hypoxia and fever often coincide
with symptoms of VOE (especially in patients who receive narcotic
medications) and may precede the radiographic changes, resulting in
delayed diagnosis and treatment.When patients admittedwith VOEde-
velop these symptoms, chest X-ray and blood counts are recommended
to assess for new inﬁltrates or an abrupt decrease in haemoglobin.
Although blood transfusions should be avoided for the treatment of
VOE, they should be considered in patients with ACS.
4.3. Stroke
Stroke is also a signiﬁcant complication in SCD,with the potential for
major morbidity and mortality [25]. In HbSS disease, the incidence of
overt stroke is 11% by age b20 years [26], and silent cerebral infarcts
are more frequent (up to 30%) [27]. A silent infarct (SI) is deﬁned as
a lesion on magnetic resonance imaging (MRI) consistent with an in-
farction, but without focal neurologic deﬁcit lasting longer than 24 h.
Despite the terminology, these lesions are not clinically silent. SIs are as-
sociated with cognitive impairment, decrement in intellectual abilities,
poor academic attainment, and increased risk for subsequent infarction
[28]. Importantly, Transcranial Doppler (TCD) testing can predict pa-
tients' risk for stroke (shown in the Stroke Prevention in Sickle Cell
Anaemia [STOP] study [29]), enabling preventative treatment with
simple and exchange transfusion therapy. Unfortunately, TCD remains
limited both in low-resource areas as well as in regions of ﬁrst-world
countries in which patients with SCD are remotely located or not seen
in large numbers [30,31].
4.4. Asthma
Asthma is also common in children with SCD, with a prevalence of
8–53% [20]. The pulmonary complications, which cannot be attributed
to genetic predisposition alone, likely reﬂect overlapping pathophysio-
logic mechanisms between SCD and asthma [32]. The presence of asth-
ma in SCDpatients increases the risk of hospitalisation for both VOE and
ACS [32]. Furthermore, asthma is an independent predictor of mortality
in patients with SCD. However, effective asthmamanagementmay help
prevent SCD-related complications [33]. In addition, patients with SCD
and asthma who are hospitalised for VOE should be treated with bron-
chodilators to prevent a concurrent asthma exacerbation.
4.5. Adult SCD
Adults with SCD experiencemany of the same symptoms as children.
However, additional disease manifestations may present or worsen aspatients age, including leg ulcers, sickle retinopathy, nephropathy, de-
creased bonedensity, thromboembolic complications, pulmonary hyper-
tension, cardiac failure, transfusional iron overload, and avascular
necrosis (Table 1) [1,2]. Causes of death in adults with SCD aremore var-
iable than in children and include infection, ACS, pulmonary emboli, liver
failure (due to iron overload), stroke, andheart failure [34–36]. For adults
with SCD, VOE is the leading admission diagnosis and the main reason
for ED visits [34,35]. Acute pain episodes peak at age 20–29 years [37],
and, in one study [38], adults reported pain on more than 50% of days,
with severe SCD-related pain reducing quality of life [1]. Adult patients
who report more than three pain crises per year have a predicted de-
creased survival [37]. Strokes in adults with SCD tend to be severe,
with ischaemic stroke (most frequent between 35 and 65 years of age)
often causing physical and cognitive disability, and haemorrhagic stroke
(most frequent in young adults) having a high mortality rate [39].
5. Disease management of SCD
Pain is the most common reason for patients with SCD to seek treat-
ment. However, although most pain experienced by SCD patients is
likely due to vaso-occlusion, there are also other mechanisms of pain
that are poorly understood. A schema for the differential diagnosis of
SCD-related pain as well as systematic approach to the treatment of
SCD-related pain are presented in Fig. 4 [40]. In addition, there is a pau-
city of specialised resources available for patients aged N18 years seek-
ing treatment for SCD-related pain. For patients presenting with acute
VOE, rapid and aggressive treatment is needed. Traditional treatments
include opioids, non-steroidal anti-inﬂammatory drugs, and hydration
[40]. Hydroxyurea (discussed below), although not helpful for acute
relief, can decrease the number of painful episodes when taken chroni-
cally. Relaxation techniques, warmth, massage, and psychological pain
management (e.g. cognitive behavioural therapy) should be consid-
ered. It is essential to examine all patients presenting with VOE for
signs of infection [41], ACS, pulmonary embolism, splenic or hepatic
sequestration, cholecystitis, stroke, or other underlying etiologies.
Many high-risk complications may also present as VOE, and thus
careful evaluation of patients with pain is critical. One study of SCD
patients aged N21 years demonstrated that more than 50% of patients
who died in the hospital were admittedwith the diagnosis of seemingly
uncomplicated VOE [42]. Transfusion therapy is not recommended for
patients with isolated pain crisis because of the signiﬁcant risk of iron
overload in patients who receive more than 20 lifetime blood transfu-
sions, as well as the propensity for allo-antibody formation.
5.1. Hydroxyurea
Hydroxyurea (HU) is currently the only established preventative
pharmacologic treatment for both paediatric and adult patients with re-
current VOEs [43,44]. The mechanism of action is partly a result of the
increased production of foetal haemoglobin, as well as decreased pro-
duction of leukocytes and reticulocytes that may contribute to vaso-
occlusion [43,44]. The Multi-Centre Study of Hydroxyurea in Sickle
Cell Anaemia (MSH) conﬁrmed its efﬁcacy in adults with SCD by reduc-
ing the number of acute VOEs and hospitalisations [45]. There are
also signiﬁcant cumulative data from several multicentre, randomised,
placebo-controlled studies in paediatric patients that demonstrate
the safety and efﬁcacy of HU in children [46–49]. Paediatric patients
maintained on the maximum tolerated dose of HU over several years
showed signiﬁcant reductions in VOEs, hospitalisations, end-organ
damage, chronic hypoxemia, and stroke without signiﬁcant neutrope-
nia, growth reduction, documented carcinogenesis, or end-organ dam-
age. HU is grossly under-utilised in high-resource countries, likely in
part because of a lack of physicians comfortable with prescribing the
medication, aswell as the current recommendations for periodic labora-
tory testing. In resource-poor environments, HU is often unavailable
or prohibited by lack of laboratory testing capabilities. However, it is
Fig. 4. Clinical management of pain and other aspects of SCD.* Morphine 0.1 mg/kg or hydromorphone 0.015–0.02 mg/kg.† Ketorolac (Toradol®) 0.5 mg/kg (max of 30 mg) or ibuprofen
(10 mg/kg). ACS, acute chest syndrome; BMP, basic metabolic panel; CBC, complete blood count; CT, computed tomography; i.v., intravenous; SCD, sickle cell disease; STAT, immediate.
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ies have not demonstrated signiﬁcant bone marrow suppression [46].
Therefore, it is reasonable that HU could be prescribed and monitored
by primary care physicians with the use of pre-set practice guidelines
and consultation with a haematologist.
5.2. Transfusion therapy
Chronic blood transfusions have been demonstrated to reduce the
risk of both primary and secondary stroke and prevent repeated ACS
[28,33,50]. Blood transfusions can be given as simple or exchange trans-
fusions in which patients' RBCs are removed by pheresis or by manual
exchange and replacedwith healthy RBCs. The aim of exchange transfu-
sion therapy is to reduce HbS to below 30%, which effectively prevents
stroke and SIs [29]. However, chronic transfusions and exchange
transfusions may lead to iron overload and iron deposition in organs
(liver, heart, pituitary, and pancreas), with end-organ damage po-
tentially occurring before the onset of symptoms. Thus, althoughblood transfusions may shorten VOE, it is important to reserve trans-
fusion therapy only for life-threatening complications such as ACS,
splenic sequestration, aplastic crisis, and cerebral infarction. Patients
with SCD should be treatedwith permissive anaemia (evenwhen the
haemoglobin level is below an individual's baseline) to prevent the
detrimental effects of iron toxicity. All patients requiring long-term
transfusion therapy or those who have received multiple lifetime
transfusions should be started on iron chelation therapy early and
monitored closely for the deleterious effects of iron overload [51].
Iron chelators, which form a complex with iron to promote its excre-
tion, include deferoxamine, deferiprone, and deferasirox, with oral
deferasirox currently being the most frequently used [52]. The gold
standard for assessing iron overload has shifted in the last decade
from liver biopsies, which are sample-dependent and invasive, to
specialized T2* MRI assessments of liver iron concentration [51].
Other options for monitoring transfusional iron overload include
serial laboratory evaluations (ferritin levels), which are much less
accurate.
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patients aged 2–26 years to predict stroke risk and initiate preventative
therapies. TCDsmeasure abnormal blood ﬂow velocity in large intracra-
nial arteries. The STOP study conclusively demonstrated that patients
with ﬂow velocity ≥200 cm/s time-averaged mean of the maximum
(TAMM) had a 10% increased risk of stroke, which can be reduced by
simple or exchange transfusions [29]. Studies have also demonstrated
that in patients who have suffered a stroke, subsequent stroke can be
preventedwithmonthly transfusion therapy [42,53,54]. HU is not effec-
tive to reduce repeat stroke outside of transfusion therapy (as shown
in the Stroke With Transfusions Changing to Hydroxyurea [SWiTCH]
study) [55]. Current studies are ongoing to evaluate the ability of HU
to prevent primary stroke in patients with abnormal TCDs (TCD With
Transfusions Changing to Hydroxyurea [TWiTCH] study).
5.3. Disease management speciﬁc to paediatrics
Management programs for paediatric patients with SCD in high-
resource areas are comprehensive and include acute care, routine pre-
vention (e.g. childhood vaccinations and monitoring of growth and
development [19]), and the treatment of complications (e.g. cardiac, re-
spiratory, and renal) [56]. Annual monitoring with TCDs, transfusion
therapy with iron-chelation therapy (if indicated), HU therapy, and/or
aggressive asthma management have also become standard of care in
most comprehensive centres, with evidence-based treatments initiated
early to prevent disease progression [57]. Careful attention is paid to
the academic achievement of children with SCD in order to screen for
possible SI, which would warrant MRI evaluation.
Haematopoietic stem cell transplantation (HSCT) is the only rec-
ognised cure for SCD [58,59], and has been shown to have an 85–90%
success rate in certain paediatric patient groups [59]. The use of HSCT
is restricted by the lack of fully matched sibling donors for many poten-
tially eligible patients [58]. Thus, newer studies are examining the use of
unrelated donors, including umbilical cord blood donors, for this patient
population. Although HSCT is associated with an increased risk of
morbidity (e.g. infertility, gonadal failure, and graft-versus-host dis-
ease) and mortality, it has been conclusively shown to improve quality
of life in high-risk patientswith SCD [55]. Unfortunately, the use of HSCT
also remains highly limited to resource-rich environments, although
people living in Africa and other areas often travel great distances for
this treatment.
5.4. Disease management speciﬁc to adults
The management of SCD is more complex in adult patients because
of additional co-morbidities, increased multi-organ involvement due
to SCD, chronic pain, psychosocial and socioeconomic factors, potential
neurocognitive impairments, and (often misguided) concerns for nar-
cotic dependence and tolerance. The lack of available specialised pro-
viders leads to difﬁculty in transitioning adolescents to adult care,
which further complicates SCD management. Adult patients require
multi-disciplinary management of chronic conditions, such as stroke,
cardiovascular complications (e.g. pulmonary hypertension), pulmo-
nary complications, kidney failure, retinopathy, bone necrosis, and leg
ulcers, by subspecialist providers. It is therefore imperative that adults
with SCD receive coordinated care led by a primary care physician in co-
ordination with a provider experienced in SCD, as well as other adult
subspecialty providers (i.e. neurology, ophthalmology, pulmonology,
cardiology, nephrology, pain management, and orthopaedics).
As in paediatrics, treatment options for SCD remain limited in adults,
with HUbeing the only approved treatment [60]. HU has been shown to
decrease pain, reduce transfusions and hospitalisations, and decrease
mortality; however, it is under-utilised. Transfusion therapy remains
efﬁcacious for SCD adults who have suffered strokes or severe ACS,
but is limited because of a lack of qualiﬁed providers comfortable with
RBC exchange therapy. Moreover, the use of transfusion therapy inadults is complicated by iron overload and allo-immunization. Thus,
many patients successfully treated with transfusion therapy in child-
hood are unable to continue that therapy as adults.
On the other hand, acute care and inpatient providers may over-
utilise transfusion for baseline anaemia or vaso-occlusive pain in adults
because of a lack of SCD management experience [61]. Patients with
SCD have a physiological adaptation to their anaemia; thus, it is crucial
to know a patient's baseline haemoglobin and transfuse only for life- or
organ-threatening complications. Iron overload is a frequent complica-
tion in adult patients with SCD and requires chelation therapy and
monitoring. Up to 10% of adult patientswith SCD are noted to have com-
plications of iron toxicity at the time of death [54].
HSCT is also curative in adults with SCD but is more difﬁcult because
of the increased risk of treatment-related complications. Newer studies
have demonstrated effective transplantation with reduced-intensity
conditioning, which may increase the options for adult patients [58,59].
Additional complications for HSCT in adults include the lack of available
donors and lack of available adult transplantation centres with expertise
in SCD.
Regardless of treatment, pain is the most-common presenting
symptom of SCD in adults. VOEs are often under-treated, which may
cause excessive hospital utilisation, including ED visits and inpatient
hospitalisations, as well as lost work productivity [62]. Concerns re-
garding addiction, dependence, and tolerance to pain medication are
often unfounded, but add an important layer of complexity to patient
care. Pain contracts between patients and providers, as well as drug-
monitoring, can be beneﬁcial, but require outpatient follow-up. The
manifestations of VOE in conjunction with a lack of preventative care
and insufﬁcient insurance coverage in this population canmake it difﬁcult
to provide effective management in adults [63]. Primary and secondary
prevention are also essential and are best addressed in a comprehensive
setting. Some key points are presented in Table 2.
6. Access to healthcare: transition frompaediatric to adult healthcare
Although many more children with SCD are living into adulthood,
there has not been a corresponding increase in medical haematologists
trained to treat older patients.
Accessing adequate health and medical services for the young adult
with SCD can be a challenge, and usually involves a change in the phy-
sician and location of care. Furthermore, the transition from paediatric
to adult care may be mired by additional issues of poor communication
between healthcare providers, lack of early disease education, limited
availability of qualiﬁed adult providers, and a lack of information or un-
derstanding about the complexity of SCD in aging patients [64–68].
Reﬁning continuity of care during transition is essential to improving
patient outcomes, with a successful transition completed when the
young adult has attained medical maturity and is receiving care in an
adult healthcare setting [68]. In contrast, the lack of a transition care
plan may have a negative impact on outcomes in young adults with
SCD. Without a designated provider, affected adults become dependent
on acute care services without the necessary ancillary support services
[68]. There is a higher re-admission and acute care utilisation rate in
patients aged 18–30 years, with dramatic increases in 30-day rates of
return to any acute care facility from 27.4% (patients aged 10–17 years)
to 48.9% (patients aged 18–30 years) [69]. This increase is especially
concerning since early rehospitalisation is associated with increased
mortality. In the US, these issues are compounded by ﬁnancial con-
straints, including the loss of medical insurance and/or decreased ﬁnan-
cial reimbursement from public insurance plans [34]. Adults who were
transitioned without a concrete plan reported feeling ill-prepared and
that their transition was based on age rather than readiness or needs.
These adult patients also reported that their follow-up care had declined
since the transfer [70].
Thus, transition programs that prepare paediatric patients with SCD
for the adult healthcare environment promote self-advocacy and self-
Table 2
Primary and secondary preventative measures in adult SCD [60,62,63].
Measure Management regimen
Vaccinations to prevent complications for
encapsulated organisms, especially in
patients with HbSS disease who likely
do not have a functional spleen
• Patients should receive a ﬂu vaccine every year, a pneumococcal vaccine every 5 years, and ameningococcal vaccine series (2-dose
primary series administered 2 months apart for persons N 2 years
• Since most patients are exposed to blood products, they should also undergo the hepatitis A and B vaccine series
Routine screening for sickle cell retinopathy • Should be done once a year
Routine screening for hypertension • Should be done at least annually
• Patients should be started on antihypertensive treatment with a goal to lower blood pressure to ≤140/90 mm Hg
Urine assessment for proteinuria • Urine should be checked for proteinuria periodically and, in case of persistent proteinuria, patients should be referred to a renal
specialist
• The use of an ACE inhibitor should be considered
Routine screening for pulmonary hypertension • Currently not indicated in asymptomatic individuals, but should be done if symptomatic
• Individuals with pulmonary hypertension have a higher risk of mortality when presenting with VOC and should be monitored
more carefully
Patients with a life-time transfusion history
of 10–20 units of blood
• Are at high risk for iron overload
• Although ferritin is not an accurate measure of iron overload (and could be markedly elevated during acute pain as an acute phase
reactant), levels of N1000 ng/mL could indicate an overloaded state; further transfusions in those individuals should be avoided
whenever possible and iron chelation should be initiated
• Further assessment with liver biopsy or FerriScan® (Resonance Health, Australia) to quantitate iron toxicity should be performed
• Patients with evidence of iron overload should be referred for outpatient management of chelation therapy
Ischaemic stroke • The etiology of ischaemic stroke in older adults with SCD is poorly understood and may have similar risk factors as non-SCD
patients in this age group
• The role of acute and chronic transfusion in adults has not been deﬁned; therefore, treatment for stroke in adult patients with SCD
is based on paediatric patients with SCD and patients should undergo exchange transfusion for acute stroke in consultation with a
haematologist
• Patients with SCD and strokemay have cognitive deﬁcits that cause difﬁculty in understanding discharge instructions and remem-
bering to keep follow-up appointments
SCD, sickle cell disease; HbSS, homozygous sickle haemoglobin mutation; ACE, angiotensin converting enzyme; VOC, vaso-occlusive crisis.
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help adolescents develop this independence and knowledge [68,71,72].
This approach links them with adult healthcare providers prior to tran-
sition in order to optimise communication, continuity of care, and col-
laboration, as well as decrease anxiety during this process.7. Future directions in the management of SCD
This review highlights several gaps in the current understanding of
SCD management throughout the patient's lifespan. Further research
should include prevalence studies in SCD, randomised-controlled as-
sessments of novel medical therapies, and improvements in transition
of care. Additional quality improvement should focus on cost-effective
preventative, comprehensive care programs for adults with SCD;
research on methods to increase HU utilisation; and cooperative trials
in alternative-donor HSCT for patients with SCD.
A better understanding of SCD, including the identiﬁcation of genetic
polymorphisms and clinical characteristics that can predict disease
severity in childhood, would also improve preventative management.
Continued studies on pharmacotherapies to reduce the occurrence of
VOE and prevent organ dysfunction/failure are also warranted.
Current knowledge about the pathophysiology of SCD provides
multiple loci for novel potential therapeutic interventions (Table 3)
[73]. Increasing the opportunity for HSCT of at-risk paediatric patientsTable 3
Potential new medications for SCD.
• Novel low-molecular-weight compounds that can alter key aspects of SCD, such as haemo
• Calcium-sensitive Gardos channel inhibitors (such as ICA-17043), with or without hydrox
• Statins to increase NO production and reduce leukocyte adhesion
• Anti-inﬂammatory drugs that inhibit NF-kB and upregulate adhesion molecules
• Intravenousγ-globulins to reduce leukocyte adhesion and the number of interactions betw
• Anti-platelet agents for preventing SCD-related platelet activation leading to vaso-occlusio
SCD, sickle cell disease; HbF, foetal haemoglobin; RBC, red blood cell; NO, nitric oxide; NF-kB, nbefore the development of organ dysfunction will also be instrumental
to improving survival. Gene therapy offers another potential cure for
SCD, but concerns over the safety of random genomic insertion need
to be resolved [74].8. Conclusions
SCD is a complex disorder with considerable variability among indi-
viduals and accumulating morbidities associated with aging, which
challenge its management. Furthermore, few treatments exist for SCD,
and the primary treatment (HU) is signiﬁcantly underused. Internation-
ally, focus needs to continue on instituting newborn screening in low-
resource countries, point-of-care testing, and early childhood care to
prevent early morbidity. Additionally, although comprehensive man-
agement programs exist for paediatric patients with SCD, there is
a need for improved transition of care to reduce early mortality in
young adults and to reduce hospital utilisation costs by preventing
over-reliance on acute care facilities. Although curative options with
HSCT exist for SCD, they still remain limited due to a lack of appropriate
donors and concerns with procedural toxicities. In high-resource coun-
tries, comprehensive coordinated care for adults with SCD remains a
priority. Until adult patientswith SCDhave access to acceptable preven-
tative care services and specialised management centres, they will con-
tinue to receive suboptimal care at unnecessarily high cost.globin polymerization, expression of HbF, and leukocyte adhesion
yurea, to prevent the dehydration of RBCs
een RBCs andwhite blood cells, and to improvemicrocirculatory blood ﬂow and survival
n and acute chest syndrome
uclear factor kappa B. Compiled from Frenette, et al. [73].
286 J. Kanter, R. Kruse-Jarres / Blood Reviews 27 (2013) 279–2879. Practice points
• The model of care of patients with sickle cell disease (SCD) should be
preventative and comprehensive in addition to acute caremanagement.
• Adults with SCD need coordinated care led by a primary care physician
in coordination with a provider experienced in SCD, as well as other
adult subspecialty providers.
• SCD shows considerable phenotypic heterogeneity resulting from
both genetic and environmental factors and different patients (with
the same genotype) may have very different symptomatology that
worsens with age.
• Patients with SCD and asthmawho are hospitalised for vaso-occlusive
episodes should be treated with bronchodilators to prevent a concur-
rent asthma exacerbation.
• Hydroxyurea can be prescribed andmonitored by primary care physi-
cians with the use of pre-set practice guidelines.
10. Research agenda
• Identiﬁcation and application of biomarkers of disease severity in sickle
cell disease
• Identiﬁcation and implementation of new disease-modifying medica-
tions to prevent or reduce vascular and endothelial damage
• Increase understanding and utilization of stem-cell transplant with
reduced-intensity preparative regimens and/or theuse of novel donors
• Projects dedicated to improving the health resources available for this
at-risk global patient population
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